Histogen $9.49 million Fundraising. Gail Naughton Filed Jun 29 form D

Stem cell; cell based hair therapy
1

Histogen Financing

Histogen Inc., Corporation just filed form D for $9.49 million equity financing. The date of first sale was 2007-12-03. Histogen was able to fundraise $9.49 million. That is 100.00% of the round of financing. The total offering amount was $9.49 million. The financing document was filed on 2015-06-29. The reason for the financing was: unspecified.
Histogen is based in Alabama. The firm’s business is Biotechnology. The SEC form was filed by Gail Naughton CEO. The company was incorporated more than five years ago. The filler’s address is: 10655 Sorrento Valley Road, San Diego, Ca, California, 92121. Gail Naughton is the related person in the form and it has address: 873 Eugenie Ave., Encinitas, Ca, California, 92024. Link to Histogen Filing: 000164582915000005.
Analysis of Histogen Offering

On average, companies in the Biotechnology sector, sell 73.77% of the total offering size. Histogen sold 100.00% of the offering. Could this mean that the trust in Histogen is high? The average offering size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 207.99% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Histogen Also

The Form D signed by Gail Naughton might help Histogen Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Read more: http://www.octafinance.com/histogen-9-49-million-fundraising-gail-naughton-filed-jun-29-form-d/87154/#ixzz3f2zZ3PUg

2

not a lot of funding for a bio tech… this won’t go far.

3

That’s what I was thinking. $10m won’t go far in that game.

4

That website is an automated “bot” that just pulls information from other sources and creates an article. It’s hard to tell if the info is accurate or current because I don’t see any other references to it. Also I can’t tell if this refers to Histogen’s hair research (HSC) or to its other products, which apparently are many.

5

This is really a very small amount of money and it is certainly not enough money to fund a phase 3 clinical trial. This small amount of money will keep them going but they will need more funding to get things like clinical trials done.